# $\alpha_1$ -Adrenergic activation of brown adipocytes leads to an increased formation of inositol polyphosphates

### Eewa Nånberg and James Putney, jr\*

Department of Metabolic Research, The Wenner-Gren Insitute, University of Stockholm, Biologihus F3, S-106 91 Stockholm, Sweden and \*Department of Phamacology, Medical College of Virginia, Richmond, VA 23298-0001, USA

### Received 6 November 1985

 $\alpha_1$ -Adrenergic activation of isolated brown adipocytes causes a rapid mobilization of intracellular  $Ca^{2+}$ . The cells also respond with an increased turnover of inositol lipids. The present work demonstrates that  $\alpha_1$ -adrenergic stimulation of brown adipocytes results in phospholipase C-mediated breakdown of phosphatidylinositol bisphosphate to form inositol trisphosphate. The rate of appearance of inositol trisphosphate is sufficiently rapid for it to mediate or contribute to  $Ca^{2+}$  mobilization in these cells.

(Brown adipocyte)  $\alpha_{i}$ -Adrenoceptor Inositol polyphosphate Li<sup>+</sup>

### 1. INTRODUCTION

Previous studies have shown that  $\alpha_1$ -adrenoceptor activation causes mobilization of intracellular Ca<sup>2+</sup> in brown adipocytes [1]. This  $\alpha_1$ -adrenergic effect is dependent on the presence of extracellular Na<sup>+</sup> [1] and may be associated with an increased Na<sup>+</sup> influx. Since the abundant mitochondria in brown adipocytes possess an active Na<sup>+</sup>/Ca<sup>2+</sup> exchange mechanism [2], it has been suggested that the  $\alpha_1$ -adrenoceptor-induced Ca<sup>2+</sup> mobilization could arise secondarily to Na<sup>+</sup> entry [1,3,4].

 $\alpha_1$ -Adrenergic stimulation of brown adipocytes also induces an increased turnover of PtdIns [5,6]. It is generally believed that agonist-activated turnover of PtdIns reflects phospholipase C-mediated breakdown of phosphatidylinositol 4,5-bisphosphate to diacylglycerol and inositol 1,4,5-trisphosphate [Ins(1,4,5)P<sub>3</sub>]. Ins(1,4,5)P<sub>3</sub> has been shown to cause Ca<sup>2+</sup> release in several different types of permeabilized cells [7–9] and from microsomal fractions from hepatocytes [10] and

Abbreviations: InsP<sub>3</sub>, inositol trisphosphate; PtdIns, phosphatidylinositol

insulinoma cells [11]. Ins(1,4,5)P<sub>3</sub> also caused EGTA-inhibited activation of pyruvate dehydrogenase in isolated white fat cells [12], which may be indicative of intracellular Ca<sup>2+</sup> release.

The aim of this work was to determine whether  $\alpha_1$ -adrenergic activation of brown adipocytes results in an increase in cellular Ins(1,4,5)P<sub>3</sub>, in the light of the possibility that this putative messenger could contribute to Ca<sup>2+</sup> mobilization in these cells.

### 2. MATERIALS AND METHODS

### 2.1. Isolation of brown adipocytes

Brown adipocytes were isolated by collagenase digestion of tissue obtained from adult golden hamsters, as described [1]. Cell viability was routinely about 90%, estimated by staining with Alcian blue.

## 2.2. Incubation of brown adipocytes and labelling of inositol lipids

All incubations were performed in Krebs-Ringer bicarbonate buffer containing 2% bovine serum albumin, 10 mM glucose and 10 mM fructose at

pH 7.4 (37°C) and under a gas phase of 5% CO<sub>2</sub> in O<sub>2</sub> (pH was continuously monitored with phenol red). Inositol lipids were labelled by incubating the adipocytes  $(1.0 \times 10^6 \text{ cells/ml})$  for 90 min in medium containing 10 µCi/ml myo-[3H]inositol. Extracellular radioactivity was removed by centrifugation and the cells were incubated for an additional 20 min at  $0.5 \times 10^6$  cells/ml. 1  $\mu$ M propranolol was added and the suspension divided into aliquots for experimental incubations. To some of the aliquots drugs were added. 1 ml samples were taken from these incubations, and the reactions stopped by precipitation with 2 ml of 4.5% perchloric acid. Perchloric acid was added to controls (t = 0) prior to the addition of drugs. The samples were left on ice for 10 min and then centrifuged. The supernatants were neutralized with 3 ml of 0.5 M KOH/9 mM Na<sub>2</sub>B<sub>4</sub>O<sub>7</sub> (pH 8). Representative aliquots were extracted with chloroform-methanol to determine total radioactivity in cellular phospholipids [13].

### 2.3. Separation of inositol phosphates

The water-soluble inositol phosphates were separated by anion-exchange chromatography on Dowex-AG1 as described by Berridge et al. [14]. Radioactivity in fractions corresponding to inositol phosphate (InsP), inositol bisphosphate (InsP<sub>2</sub>) and InsP<sub>3</sub> were determined and expressed as a percentage of the radioactivity in total lipids, or as a percentage of control (t = 0) radioactivity.

### 2.4. Materials

myo-[<sup>3</sup>H]Inositol was obtained from American Radiochemicals, Dowex-AG1 from Bio-Rad, norepinephrine bitartrate, propranolol-HCl and yohimbine-HCl from Sigma. Prazosin-HCl was a gift from Pfizer.

### 3. RESULTS AND DISCUSSION

Norepinephrine (10  $\mu$ M) caused a modest, but statistically significant increase in [ $^3$ H]InsP $_3$  1 min after its addition (P < 0.05; n = 5); data are shown in fig.1. Also shown are the effects of norepinephrine when 20 mM LiCl [15] was present 20 min prior to, and during, stimulation. Li<sup>+</sup> did not affect the basal or initial (1 min) increase in InsP $_3$ , but markedly potentiated the increase in InsP $_3$  level 5 and 10 min after the addition of




Fig. 1. Effect of Li<sup>+</sup> on basal and agonist-stimulated levels of InsP<sub>3</sub> in brown adipocytes. [ $^3$ H]Inositol-loaded cells were resuspended in fresh buffer and incubated with or without 20 mM LiCl for 20 min (controls received 20 mM NaCl). At 20 min, 1  $\mu$ M propranolol followed by 10  $\mu$ M norepinephrine were added and the incubation continued for another 10 min. ( $\square$ ) – Li<sup>+</sup>, ( $\blacksquare$ ) + Li<sup>+</sup>. The radioactivity in the InsP<sub>3</sub> fraction is here calculated as % of the cpm in the total phospholipid fraction. Points shown are means from 3 parallel experiments ( $\pm$  SE). (\*) and (\*\*) show significant increases above the pre-norepinephrine level at 20 min (P < 0.05 and < 0.01, respectively); + shows significant effect of Li (P < 0.05); Student's paired t-test.

norepinephrine. A similar effect was noted for InsP<sub>2</sub> and InsP, but for InsP the relative changes due to hormone or Li<sup>+</sup> were much smaller (not shown; cf. fig.2). This concentration of Li<sup>+</sup> did not affect cell viability and only slightly ( $\leq 10\%$ ) suppressed the norepinephrine-induced respiratory response (this response is mainly a  $\beta$ -adrenergic effect but the slight suppression was sustained when the  $\alpha_1$ -adrenergic component of respiration was inhibited by prazosin; thus it was not due to a selective inhibition of the  $\alpha_1$ -component).

In the experiments,  $1 \mu M$  propranolol was routinely added to diminish the oxygen consumption of the cells and thus ensure an adequate ox-

ygen supply. Garcia-Sainz et al. [5,16] have reported an increased incorporation of  $^{32}P$  into PtdIns in the presence of a high concentration of propranolol. This is probably due to inhibition of phosphatidic acid phosphohydrolase; however, in preliminary experiments (not shown),  $1 \mu$ M propranolol did not affect the incorporation of [ $^{3}H$ ]-inositol into inositol phosphates in this system.

Fig.2 shows the time course of the effect of  $10 \,\mu\text{M}$  norepinephrine, in the presence of 20 mM Li<sup>+</sup>, on [<sup>3</sup>H]InsP<sub>3</sub>, [<sup>3</sup>H]InsP<sub>2</sub> and [<sup>3</sup>H]InsP levels in brown adipocytes. Changes in InsP levels were, relative to the control level, smaller than for InsP2 and InsP<sub>3</sub> and thus statistically less reliable (note the difference in ordinate scales). Norepinephrine induced an increase in both InsP<sub>2</sub> and InsP<sub>3</sub> already at the earliest time point examined, 15 s. This indicates that polyphosphoinositide hydrolysis may initiate inositol lipid cycling in brown adipocytes and that earlier reports on increased PtdIns synthesis being stimulated by  $\alpha$ -adrenergic activation [5.6] may be understood as a resynthesis after polyphosphoinositide breakdown, as shown for a number of other cell systems [17,18]. The increases in both InsP2 and InsP3 were unaffected by the  $\alpha_2$ -adrenoceptor antagonist yohimbine  $(0.1 \,\mu\text{M})$  but were completely blocked by the  $\alpha_1$ -adrenoceptor antagonist, prazosin, at the same concentration. This result is consistent with the reported findings of Garcia-Sainz et al. [5] and of Mohell et al. [6] who showed that prazosin was a much more potent blocker than vohimbine of the phenylephrine-stimulated PtdIns turnover. The increase in InsP3 is at least as rapid as the previously described  $\alpha_1$ -adrenergic Ca<sup>2+</sup> mobilization in these cells [1], suggesting that release of Ca<sup>2+</sup> by InsP<sub>3</sub> could well contribute to this response.

One problem in relating levels of InsP<sub>3</sub> as determined by anion exchange to biological responses is the recent finding that the tritiated material formed it some cells is a mixture of isomers, specifically Ins(1,4,5)P<sub>3</sub> and Ins(1,3,4)P<sub>3</sub> [19, 20,22]. In different systems, Ins(1,4,5)P<sub>3</sub> has been shown to release intracellular Ca<sup>2+</sup> [17]. While Ins(1,3,4)P<sub>3</sub> has not been tested directly, there is indirect evidence that it does not mobilize Ca<sup>2+</sup> [20]. In the present study, [<sup>3</sup>H]InsP<sub>3</sub> was not resolved into the 2 isomers. There are interesting parallels, however, between these data and those of Burgess et al. [20] and Rubin [21] with liver and




Fig.2. Effect of norepinephrine on the formation of inositol phosphates in brown adipocytes. [3H]Inositolloaded cells were preincubated for 20 min in the presence of 20 mM LiCl. At 20 min, 1 µM propranolol was added and after another minute, 0.1 µM prazosin, 0.1 µM yohimbine or buffer. Immediately thereafter 10 μM norepinephrine was added. The amount of [3H]inositol phosphates was measured and is presented as % of control values (100% thus corresponds to the level of the inositol phosphates in the batch, before the additions). The data represent mean values from 3 experiments; bars indicate ± SE. Observe that the scale is adjusted so that the absolute amount of cpm is identical for all 3 panels (mean % of total phospholipid label was 28.7, 0.72, and 0.28 for InsP, InsP<sub>2</sub> and InsP<sub>3</sub>, respectively).

exocrine pancreas which permit some speculation on the isomers formed. In the pancreas, as for the brown fat cells, Li<sup>+</sup> potentiates [<sup>3</sup>H]InsP<sub>3</sub> accumulation. In pancreas, this potentiation occurs after 2 min of stimulation [21] and is totally accounted for by the Ins(1,3,4)P<sub>3</sub> isomer, Ins (1,4,5)P<sub>3</sub> not being affected by Li<sup>+</sup> at all [20]. This finding is consistent with reports that during the initial minute after receptor activation, only the  $Ins(1,4,5)P_3$  isomer is increased [20,22]. Thus, the pattern of [3H]InsP<sub>3</sub> production in the brown adipocyte would suggest that the initial increase, in the first minute or so, is largely  $Ins(1,4,5)P_3$ , while the Li<sup>+</sup>-sensitive material which accumulates with more prolonged stimulation may be primarily Ins(1,3,4)P<sub>3</sub>. Studies are currently under way to examine more directly these isomers in the brown adipocyte system.

In summary, these results demonstrate that inositol lipid turnover in the brown adipocyte results from an  $\alpha_1$ -adrenoceptor-mediated phosphodiesteratic breakdown of polyphosphoinositides, liberating soluble inositol phosphates. The formation of InsP<sub>3</sub> is rapid enough to enable it to contribute to the previously described intracellular Ca<sup>2+</sup> mobilization in these cells.

### **ACKNOWLEDGEMENTS**

This work was supported by NIH grants nos DE-05764 and AM-32823. E.N. was the recipient of grants from Aqvists fond and Wallenbergs Jubileumsfond and of support from Magnus Bergvalls Stiftelse and The Swedish Natural Science Research Council (to Barbara Cannon and Jan Nedergaard). We wish to thank Gillian M. Burgess and Jan Nedergaard for valuable help and discussions.

#### REFERENCES

- [1] Connolly, E., Nånberg, E. and Nedergaard, J. (1984) Eur. J. Biochem. 141, 187-193.
- [2] Al-Shaikhaly, M.H.M., Nedergaard, J. and Cannon, B. (1979) Proc. Natl. Acad. Sci. USA 76, 2350-2353.
- [3] Nedergaard, J. (1983) Eur. J. Biochem. 133, 185-191.
- [4] Nedergaard, J., Connolly, E., Nånberg, E. and Mohell, N. (1984) Biochem. Soc. Trans. 12, 393-396.
- [5] Garcia-Sainz, J.A., Hasler, A.K. and Fain, J.N. (1980) Biochem. Pharmacol. 29, 3330-3333.
- [6] Mohell, N., Wallace, M. and Fain, J.N. (1984) Mol. Pharmacol. 25, 64-69.
- [7] Streb, H., Irvine, R.F., Berridge, M.J. and Schulz,I. (1983) Nature 306, 67-68.
- [8] Burgess, G.M., Godfrey, P.P., McKinney, J.S., Berridge, M.J., Irvine, R.F. and Putney, J.W. jr (1984) Nature 309, 63-66.
- [9] Joseph, S.K., Thomas, A.P., Williams, R.J., Irvine, R.F. and Williamson, J.R. (1984) J. Biol. Chem. 259, 3077-3081.
- [10] Dawson, A.P. and Irvine, R.F. (1984) Biochem. Biophys. Res. Commun. 120, 858-864.
- [11] Prentki, M., Biden, T.J., Janjic, D., Irvine, R.F., Berridge, M.J. and Wollheim, C.B. (1984) Nature 309, 562-564.
- [12] Koepfer-Hobelsberger, B. and Wieland, O.H. (1984) FEBS Lett. 176, 411-413.
- [13] Weiss, S.J., McKinney, J.S. and Putney, J.W. jr (1982) Biochem. J. 206, 555-560.
- [14] Berridge, M.J., Dawson, R.M.C., Downes, C.P., Heslop, J.P. and Irvine, R.F. (1983) Biochem. J. 212, 473-482.
- [15] Berridge, M.J., Downes, C.P. and Hanley, M.R. (1982) Biochem. J. 206, 587-595.
- [16] Garcia-Sainz, J.A. and Fain, J.N. (1980) Biochem. J. 186, 781-789.
- [17] Berridge, M.J. and Irvine, R.F. (1984) Nature 312, 315-321.
- [18] Aub, D.L. and Putney, J.W. jr (1984) Life Sci. 34, 1347-1355.
- [19] Irvine, R.F., Letcher, A.J., Lander, D.J. and Downes, C.P. (1984) Biochem. J. 223, 237-243.
- [20] Burgess, G.M., McKinney, J.S., Irvine, R.F. and Putney, J.W. jr (1985) Biochem. J. 232, 000.
- [21] Rubin, P.R. (1984) J. Pharmacol. Exp. Ther. 231, 623-627.
- [22] Irvine, R.F., Änggård, E.E., Letcher, A.J. and Downes, C.P. (1985) Biochem. J. 229, 505-511.